Compare Cytokinetics Inc (CYTK) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Consumer Discretionary Select Sector SPDR Fund trades at $115.97. The key difference: Cytokinetics Inc is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| CYTK | XLY | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | — |
52-Week High | $87.26 | $124.52 |
52-Week Low | $33.23 | $105.64 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
XLY trades at $116.04, down 1.02% today amid a bearish technical signal with selling pressure outweighing buys 12 to 4. Analyst consensus is unanimously bullish with a 100% buy rating. Recent news highlights consumer discretionary as a potential sleeper opportunity for Q3 2026, though inflation and weak consumer sentiment pose headwinds. The stock shows neutral oscillators but bearish moving averages, with support at $114 and resistance at $118.
The outlook for XLY is cautiously optimistic given strong analyst support, but risks include persistent inflation eroding discretionary spending and technical weakness. Investment opportunity hinges on a consumer spending rebound, while key risks are macroeconomic pressures and sector underperformance. The dividend scheduled for June 2026 offers minor income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
